Evaluation of the Optimal Concentration Range of Adalimumab for Ankylosing Spondylitis in a Prospective Observational Cohort Study

• Status: Not yet recruiting
• Trial end date: 2023-04-20
• Target enrollment: 500
• Participant gender: All

Summary

Objective to evaluate the optimal concentration range of adalimumab in as population

To evaluate the predictive effect of early plasma concentration on treatment response

Exploring potential biomarkers for predicting therapeutic response

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital of Soochow University
• Treatments: Adalimumab

Criteria

Inclusion Criteria:

Clinical diagnosis of ankylosing spondylitis Injection of adalimumab

Exclusion Criteria:

Hepatitis B patients Tuberculosis patients